Romina Lomonaco

Romina Lomonaco, MD

Clinical Assistant Professor

Department: MD-ENDOCRINOLOGY
Business Phone: (352) 273-8655

About Romina Lomonaco

Romina Lomonaco, M.D. is an assistant professor of medicine in the division of Endocrinology, Diabetes and Metabolism. She received her medical degree from Universidad Nacional del Nordeste, School of Medicine in Argentina. Dr. Lomonaco completed a research fellowship, focusing on diabetes at the University of Texas Health Science Center at San Antonio. She has continued her studies at the University of Florida by completing a residency in internal medicine, followed by a fellowship in endocrinology.

Dr. Lomonaco is a member of the Endocrine Society, American Diabetes Association and American Association of Clinical Endocrinologists.

Accomplishments

CTSI Pilot Project Award
2012-2013 · UF Clinical and Translational Science Institute

Clinical Profile

Subspecialties
  • Endocrinology, Diabetes and Metabolism
Areas of Interest
  • Diabetes
  • High blood cholesterol levels
  • Obesity

Research Profile

Romina Lomonaco, M.D. has been involved in clinical research in adult endocrinology, mainly in the metabolism field. She has participated in clinical trials related to Type 2 diabetes associated to nonalcoholic fatty liver disease, or NAFLD. Her current research interest focuses in understanding the metabolic impact that NAFLD, and specifically its more severe form nonalcoholic steatohepatitis, or NASH, has in patients with Type 2 diabetes and/or obesity. She has also been involved in clinical trials assessing different drugs that could potentially be used to treat this condition.

Dr. Lomonaco has numerous publications including original articles, reviews and book chapters in the main journals in the fields of diabetes, obesity and liver disease.

She specializes in treating patients with diabetes and other metabolic diseases such as dyslipidemia and obesity.

Areas of Interest
  • Diabetes
  • Type 2 Diabetes

Publications

2021
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.
Diabetes care. 44(2):399-406 [DOI] 10.2337/dc20-1997. [PMID] 33355256.
2021
Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes.
The Journal of clinical endocrinology and metabolism. 106(11):e4360-e4371 [DOI] 10.1210/clinem/dgab417. [PMID] 34190318.
2020
Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
Journal of hepatology. 72(3):401-410 [DOI] 10.1016/j.jhep.2019.09.018. [PMID] 31589891.
2019
Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial.
Journal of diabetes. 11(3):223-231 [DOI] 10.1111/1753-0407.12833. [PMID] 30073778.
2019
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Diabetes care. 42(8):1481-1488 [DOI] 10.2337/dc19-0167. [PMID] 31332029.
2018
Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 16(4):558-566.e2 [DOI] 10.1016/j.cgh.2017.12.001. [PMID] 29223443.
2017
Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
The Journal of clinical endocrinology and metabolism. 102(8):2950-2961 [DOI] 10.1210/jc.2017-00867. [PMID] 28575232.
2017
Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.). 65(4):1132-1144 [DOI] 10.1002/hep.28985. [PMID] 27981615.
2016
Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
The Journal of clinical endocrinology and metabolism. 101(2):644-52 [DOI] 10.1210/jc.2015-3111. [PMID] 26672634.
2016
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Annals of internal medicine. 165(5):305-15 [DOI] 10.7326/M15-1774. [PMID] 27322798.
2016
Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes.
Diabetes care. 39(4):632-8 [DOI] 10.2337/dc15-1876. [PMID] 26861926.
2016
Plasma thyroid hormone concentration is associated with hepatic triglyceride content in patients with type 2 diabetes.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 64(1):63-8 [DOI] 10.1136/jim-2015-000019. [PMID] 26755815.
2015
Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients.
Liver international : official journal of the International Association for the Study of the Liver. 35(9):2139-46 [DOI] 10.1111/liv.12840. [PMID] 25847730.
2015
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
The Journal of clinical endocrinology and metabolism. 100(6):2231-8 [DOI] 10.1210/jc.2015-1966. [PMID] 25885947.
2015
Relationship of Vitamin D With Insulin Resistance and Disease Severity in Non-Alcoholic Steatohepatitis
. 62(2):405-411
2015
Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis.
Journal of hepatology. 62(2):405-11 [DOI] 10.1016/j.jhep.2014.08.040. [PMID] 25195551.
2015
The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.). 61(1):153-60 [DOI] 10.1002/hep.27395. [PMID] 25145475.
2014
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
The Journal of clinical endocrinology and metabolism. 100(5) [DOI] 10.1210/jc.2014-2739. [PMID] 25303488.
2014
Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.
Journal of hepatology. 60(1):167-74 [DOI] 10.1016/j.jhep.2013.07.042. [PMID] 23973932.
2014
Multivariate Analysis of Factors That Influence Improvement in Nonalcoholic Fatty Liver Disease (Nafld) After Pioglitazone Treatment.
Pharmacotherapy. 34(10)
2014
Pharmacodynamic Association of Pioglitazone and Its Active Metabolites With Liver Outcomes Among Patients Diagnosed With Nonalcoholic Steatohepatitis.
Clinical Pharmacology & Therapeutics. 95(1)
2014
Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis.
Hepatology (Baltimore, Md.). 59(6):2178-87 [DOI] 10.1002/hep.26988. [PMID] 24777953.
2013
Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
Drugs. 73(1):1-14 [DOI] 10.1007/s40265-012-0004-0. [PMID] 23329465.
2013
Plasma Branch Chain and Aromatic Amino Acid Levels Are Associated With Insulin Resistance in Nonalcoholic Fatty Liver Disease (Nafld)
The FASEB's Journal. 27
2013
The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.
Current diabetes reports. 13(3):329-41 [DOI] 10.1007/s11892-013-0378-8. [PMID] 23625197.
2012
Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.). 55(5):1389-97 [DOI] 10.1002/hep.25539. [PMID] 22183689.
2012
Metabolic and Histological Effects of Liver Fat Accumulation in Patients With Nash
Higher Education Policy. 56
2012
Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD).
Diabetes care. 35(4):873-8 [DOI] 10.2337/dc11-1849. [PMID] 22374640.
2012
The Challenge of Managing Dyslipidemia in Patients With Nonalcoholic Fatty Liver Disease
Clinical Lipidology. 7(4):471-481 [DOI] 10.2217/CLP.12.47.
2011
An endocrine perspective of nonalcoholic fatty liver disease (NAFLD)
. 211-225
2011
An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).
Therapeutic advances in endocrinology and metabolism. 2(5):211-25 [DOI] 10.1177/2042018811419157. [PMID] 23148186.
2011
Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis.
Hepatology (Baltimore, Md.). 54(3):837-45 [DOI] 10.1002/hep.24483. [PMID] 21674556.

Grants

Jul 2007 – Aug 2016
Clinical and Translational Science Institute
Role: Project Manager
Funding: UF RESEARCH FOU

Education

Fellowship – Endocrinology
2016-2018 · University of Florida
Residency – Internal Medicine
2013-2016 · University of Florida
Research Fellowship – Diabetes Division
2009-2011 · UTHSCSA – University of Texas Health Science Center at San Antonio
Medical Degree
2005 · Universidad Nacional del Nordeste, Corrientes, Argentina

Contact Details

Phones:
Business:
(352) 273-8655
Addresses:
Business Mailing:
PO Box 100226
GAINESVILLE FL 32610